619.541.6609

We are available 24/7

CLAIMS ASSISTANCE 619.541.6609

Current Number of Drug Injury Claims Filed In Onglyza and Kombiglyze XR MDL Case

Posted on 9th August, 2019

by Legal Staff

Potential Ongylza and Kombiglyze XR cases are being evaluated on behalf of individuals nationwide as a result of the manufacturers' (AstraZeneca and its former partner Bristol-Myers Squibb) failure to warn about the different side effects of the medication on patients' health. Cases pending in the federal court system were combined in 2018 as part of a federal MDL, or multidistrict litigation.

This means that because of their similar nature, the cases are proceeding as one for coordinated discovery and pretrial proceedings. However, due to differences in each plaintiff's own circumstances, they are not being treated as a class action suit. The litigation is centralized in the U.S. District Court for the Eastern District of Kentucky.

The current number of cases filed in this diabetes drug MDL case can be found out by consulting the current version of the MDL statistics report published by the United States Judicial Panel on Multidistrict Litigation (JPML).

IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) products liability litigation MDL-2809:

  • Number of lawsuits pending: 269
  • Total action (historical): 292
  • Primary side effect for these cases: heart failure

Claims Relating to Onglyza and Kombiglyze

People injured by Onglyza and Kombiglyze have brought product liability claims against the manufacturers of the drugs. Plaintiffs set forth allegations that the manufacturers did not sufficiently examine the relationship between these drugs and incidents that may cause damage to the heart.

The claims further allege that the heart failures experienced by patients were a result of the drugmakers' negligence in designing and producing these two medications.

Also, they accuse the drugmakers of failing to do their duty of warning the public about the dangers of these drugs. The manufacturers are alleged to have sold the products (Onglyza since 2009 and Kombiglyze XR since 2010) without adequate testing and before they had a full understanding of the possible damage that they could cause to a patient's heart. The manufacturers were fully informed of the possible complications associated with these drugs only in 2013 after receiving the results of a study they had funded.

However, the manufacturers should have known that the medications were possibly linked to heart failure even before 2013, especially given the FDA's specific direction for them to undertake further study. The plaintiffs also allege that material facts indicating that these products were dangerous were suppressed by the drugmakers.

If you or a loved one has taken these medications and believes that he or she has experienced side effects, Atraxia Law can help. When you contact us, we'll look at the facts of the matter and help you determine if you are eligible to file a claim for compensation. Talk to one of the members of our team of experts to learn about your prospects for recovering damages for the harms that you have suffered.